Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC
Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC
Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC
SIOG 2024: Updates in medical oncology
Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results
SABCS 2024: Highlights in breast cancer genomic testing
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL
Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL